A biotech innovative and manufacturing company, iBio, Inc. (NYSE: IBIO) shares soared 17.93% in the aftermarket trading on Tuesday, December 1, 2020, after the company officially announced that it has entered into its first declaration of work to manufacture its bioengineered antibody-toxin fusion proteins using the FastPharming Method of iBio under a Master Services Arrangement with Belgium-based ATB Therapeutics.
The fusion proteins, or atbodies, are engineered to treat cancers. A production process and assays for selected atbodies per the SoW will be designed by iBio.
Tom Isett, Chairman & CEO of iBio, said that we are delighted to be selected as the process growth and distribution partner for atbtherapeutics, whose platform technology provides a novel solution to hard-to-treat haematological malignancies and solid tumors.
